The Manufacturers Life Insurance Company Has $260,000 Holdings in Audentes Therapeutics Inc (NASDAQ:BOLD)

The Manufacturers Life Insurance Company raised its position in Audentes Therapeutics Inc (NASDAQ:BOLD) by 1,086.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,580 shares of the biotechnology company’s stock after buying an additional 12,435 shares during the period. The Manufacturers Life Insurance Company owned 0.06% of Audentes Therapeutics worth $260,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of BOLD. Redmile Group LLC increased its stake in shares of Audentes Therapeutics by 77.8% during the 2nd quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock worth $27,922,000 after purchasing an additional 638,780 shares during the last quarter. State Street Corp increased its stake in shares of Audentes Therapeutics by 231.6% during the 2nd quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock worth $4,234,000 after purchasing an additional 154,544 shares during the last quarter. OxFORD Asset Management LLP purchased a new stake in shares of Audentes Therapeutics during the 2nd quarter worth approximately $428,000. Virtu KCG Holdings LLC purchased a new stake in shares of Audentes Therapeutics during the 2nd quarter worth approximately $257,000. Finally, Parametric Portfolio Associates LLC increased its stake in shares of Audentes Therapeutics by 113.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 36,334 shares of the biotechnology company’s stock worth $695,000 after purchasing an additional 19,274 shares during the last quarter. Hedge funds and other institutional investors own 78.95% of the company’s stock.

Audentes Therapeutics Inc (BOLD) traded down $0.58 on Friday, reaching $31.25. 152,015 shares of the company traded hands, compared to its average volume of 197,577. The company has a market cap of $950.30, a P/E ratio of -8.95 and a beta of -0.18. Audentes Therapeutics Inc has a 52 week low of $13.90 and a 52 week high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.88) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.88). equities research analysts predict that Audentes Therapeutics Inc will post -3.51 EPS for the current year.

In related news, VP Suyash Prasad sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $28.53, for a total value of $228,240.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mary Newman sold 10,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $26.84, for a total transaction of $268,400.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,000 shares of company stock valued at $1,750,480. 47.30% of the stock is owned by insiders.

Several equities research analysts have recently issued reports on BOLD shares. Leerink Swann restated an “outperform” rating and set a $29.00 price target (up previously from $22.00) on shares of Audentes Therapeutics in a research note on Wednesday, November 15th. Zacks Investment Research lowered shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Bank of America restated a “buy” rating and set a $33.00 price target (up previously from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. BidaskClub lowered shares of Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th. Finally, Raymond James Financial started coverage on shares of Audentes Therapeutics in a research note on Thursday, October 12th. They set a “market perform” rating for the company. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Audentes Therapeutics has an average rating of “Buy” and a consensus target price of $29.38.

WARNING: “The Manufacturers Life Insurance Company Has $260,000 Holdings in Audentes Therapeutics Inc (NASDAQ:BOLD)” was posted by Week Herald and is the property of of Week Herald. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://weekherald.com/2017/12/30/the-manufacturers-life-insurance-company-increases-position-in-audentes-therapeutics-inc-bold.html.

Audentes Therapeutics Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply